logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10736910 B1

PDFFull Text
Date of Patent:
Aug. 11, 2020

Filed:

Sep. 13, 2018

Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits

Applicant:

Stc.unm, Albuquerque, NM (US);

Inventors:

Vojo P. Deretic, Placitas, NM (US);

Eliseo F. Castillo, Albuquerque, NM (US);

Assignee:

STC.UNM, Albuquerque, NM (US);

Attorneys:

Henry D. Coleman

R. Neil Sudol

Primary Examiner:

My-Chau T Tran

Int. Cl.
CPC ...
A61K 31/704 (2006.01); A61K 45/06 (2006.01); A61K 31/436 (2006.01); A61K 31/00 (2006.01); A61K 31/506 (2006.01); A61K 31/713 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); G01N 33/68 (2006.01); A61K 31/277 (2006.01); A61K 31/38 (2006.01); A61K 31/381 (2006.01); A61K 31/4184 (2006.01); A61K 31/4365 (2006.01); A61K 31/4453 (2006.01); A61K 31/4535 (2006.01); A61K 31/472 (2006.01); A61K 31/473 (2006.01); A61K 31/475 (2006.01); A61K 31/495 (2006.01); A61K 31/5415 (2006.01); A61K 31/57 (2006.01); A61K 31/65 (2006.01); A61K 38/17 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 9/00 (2006.01); A61P 31/06 (2006.01); A61P 11/12 (2006.01); A61P 31/04 (2006.01); A61P 11/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/704 (2013.01); A61K 31/00 (2013.01); A61K 31/277 (2013.01); A61K 31/38 (2013.01); A61K 31/381 (2013.01); A61K 31/4184 (2013.01); A61K 31/436 (2013.01); A61K 31/4365 (2013.01); A61K 31/4453 (2013.01); A61K 31/4535 (2013.01); A61K 31/472 (2013.01); A61K 31/473 (2013.01); A61K 31/475 (2013.01); A61K 31/495 (2013.01); A61K 31/506 (2013.01); A61K 31/5415 (2013.01); A61K 31/57 (2013.01); A61K 31/65 (2013.01); A61K 31/713 (2013.01); A61K 38/177 (2013.01); A61K 38/1793 (2013.01); A61K 45/06 (2013.01); C07K 16/245 (2013.01); C07K 16/28 (2013.01); G01N 33/5055 (2013.01); G01N 33/5695 (2013.01); G01N 33/6842 (2013.01); G01N 33/6893 (2013.01); A61K 9/0073 (2013.01); A61K 38/00 (2013.01); A61P 11/10 (2018.01); A61P 11/12 (2018.01); A61P 31/04 (2018.01); A61P 31/06 (2018.01); C07K 2317/76 (2013.01); G01N 2333/4703 (2013.01); G01N 2333/4719 (2013.01); G01N 2333/4724 (2013.01); G01N 2333/54 (2013.01); G01N 2333/545 (2013.01); G01N 2333/90212 (2013.01); G01N 2500/02 (2013.01); G01N 2500/20 (2013.01);
Abstract

In one embodiment, the invention provides a method of treating a subject suffering from ainfection by administering to the subject a therapeutically-effective amount of a degradative autophagy agonist or a secretory autophagy antagonist. In another embodiment, the invention provides a method of treating a subject suffering from one or more diseases selected from the group consisting of ainfection, an inflammatory disorder, an immune disorder, a cancer and a neurodegenerative disorder by administering to the subject a therapeutically-effective amount of a TBK-1 antagonist (e.g. BX795 or amlexanox). Related pharmaceutical compositions, diagnostic and screening assays and kits are also provided.

Find Patent Forward Citations

Loading…